• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

补体替代途径自身免疫异常在膜增生性肾小球肾炎和 C3 肾小球病中的作用。

Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

机构信息

IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Clinical Research Center for Rare Diseases "Aldo e Cele Daccò", Ranica, Bergamo, Italy.

Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.

出版信息

Pediatr Nephrol. 2019 Aug;34(8):1311-1323. doi: 10.1007/s00467-018-3989-0. Epub 2018 Jun 9.

DOI:10.1007/s00467-018-3989-0
PMID:29948306
Abstract

Membranoproliferative glomerulonephritis (MPGN) is a rare chronic kidney disease associated with complement activation. Recent immunofluorescence-based classification distinguishes between immune complex (IC)-mediated MPGN, with glomerular IgG and C3 deposits, and C3 glomerulopathies (C3G), with predominant C3 deposits. Genetic and autoimmune abnormalities causing hyperactivation of the complement alternative pathway have been found as frequently in patients with immune complex-associated MPGN (IC-MPGN) as in those with C3G. In the last decade, there have been great advances in research into the autoimmune causes of IC-MPGN and C3G. The complement-activating autoantibodies called C3-nephritic factors (C3NeFs), which are present in 40-80% of patients, form a heterogeneous group of autoantibodies that stabilise the C3 convertase or the C5 convertase of the alternative pathway or both. A few patients, mainly with IC-MPGN, carry autoantibodies directed against the two components of the alternative pathway C3 convertase, factors B and C3b. Finally, autoantibodies against factor H, the main regulator of the alternative pathway, have been reported in a small proportion of patients with IC-MPGN or C3G. The identification of distinct pathogenetic patterns leading to kidney injury and of targets in the complement cascade may pave the way for tailored therapies for IC-MPGN and C3G, with specific complement inhibitors in the development pipeline.

摘要

膜增生性肾小球肾炎(MPGN)是一种罕见的慢性肾脏疾病,与补体激活有关。最近基于免疫荧光的分类方法将免疫复合物(IC)介导的 MPGN 与肾小球 IgG 和 C3 沉积物区分开来,以及 C3 肾小球病(C3G)与主要 C3 沉积物区分开来。导致补体替代途径过度激活的遗传和自身免疫异常在免疫复合物相关 MPGN(IC-MPGN)患者和 C3G 患者中同样常见。在过去的十年中,对 IC-MPGN 和 C3G 的自身免疫病因的研究取得了重大进展。补体激活自身抗体称为 C3 肾炎因子(C3NeFs),存在于 40-80%的患者中,形成了一组异质性的自身抗体,稳定 C3 转化酶或替代途径的 C5 转化酶或两者。少数患者,主要是 IC-MPGN,携带针对替代途径 C3 转化酶的两个成分,即因子 B 和 C3b 的自身抗体。最后,在一小部分 IC-MPGN 或 C3G 患者中报告了针对替代途径主要调节剂因子 H 的自身抗体。导致肾脏损伤的不同发病模式的鉴定以及补体级联中的靶点可能为 IC-MPGN 和 C3G 量身定制治疗铺平道路,在开发管道中具有特定的补体抑制剂。

相似文献

1
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.补体替代途径自身免疫异常在膜增生性肾小球肾炎和 C3 肾小球病中的作用。
Pediatr Nephrol. 2019 Aug;34(8):1311-1323. doi: 10.1007/s00467-018-3989-0. Epub 2018 Jun 9.
2
Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.阐明 C3G 和 IC-MPGN 中肾炎因子导致补体失调的分子机制。
Front Immunol. 2018 Oct 15;9:2329. doi: 10.3389/fimmu.2018.02329. eCollection 2018.
3
Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.C3 肾小球病与免疫复合物介导的膜增生性肾小球肾炎患者经典途径过度激活的不同方面。
Front Immunol. 2021 Aug 11;12:715704. doi: 10.3389/fimmu.2021.715704. eCollection 2021.
4
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.补体旁路功能失调所致增生性肾小球肾炎。
Clin J Am Soc Nephrol. 2011 May;6(5):1009-17. doi: 10.2215/CJN.07110810. Epub 2011 Mar 17.
5
Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.聚类分析确定 C3 肾小球病/免疫复合物介导的膜增生性 GN 中的不同发病模式。
J Am Soc Nephrol. 2018 Jan;29(1):283-294. doi: 10.1681/ASN.2017030258. Epub 2017 Oct 13.
6
Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.补体基因变异决定免疫球蛋白相关MPGN和C3肾小球病的风险,并预测长期肾脏结局。
Mol Immunol. 2016 Mar;71:131-142. doi: 10.1016/j.molimm.2016.01.010. Epub 2016 Feb 16.
7
Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.肾小球系膜旁沉积物:与Ⅰ型和Ⅲ型膜增生性肾小球肾炎低补体血症的关联
Am J Kidney Dis. 1998 Mar;31(3):427-34. doi: 10.1053/ajkd.1998.v31.pm9506679.
8
Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.儿童和青少年膜增生性肾小球肾炎和 C3 肾小球病的结局。
Pediatr Nephrol. 2018 Dec;33(12):2289-2298. doi: 10.1007/s00467-018-4034-z. Epub 2018 Sep 20.
9
C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.C3肾小球病中的C4肾炎因子:病例系列
Am J Kidney Dis. 2017 Dec;70(6):834-843. doi: 10.1053/j.ajkd.2017.07.004. Epub 2017 Aug 24.
10
Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.C3肾小球病和Ig相关膜增生性肾小球肾炎中的抗B因子和抗C3b自身抗体
J Am Soc Nephrol. 2017 May;28(5):1603-1613. doi: 10.1681/ASN.2016030343. Epub 2017 Jan 17.

引用本文的文献

1
Autoantibodies Against Factor B and Factor H Without Pathogenic Effects in a Patient with Immune Complex-Mediated Membranoproliferative Glomerulonephritis.免疫复合物介导的膜增生性肾小球肾炎患者中针对补体B因子和H因子的自身抗体无致病作用
Biomedicines. 2025 Mar 6;13(3):648. doi: 10.3390/biomedicines13030648.
2
Acquired drivers of C3 glomerulopathy.C3肾小球病的后天性驱动因素。
Clin Kidney J. 2025 Jan 27;18(3):sfaf022. doi: 10.1093/ckj/sfaf022. eCollection 2025 Mar.
3
Challenges in the Diagnosis and Management of Immune Complex-Mediated Membranoproliferative Glomerulonephritis and Complement 3 Glomerulopathy.

本文引用的文献

1
Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease.抗H因子抗体影响一名致密物沉积病患者的H因子辅因子活性。
Clin Kidney J. 2012 Apr;5(2):133-136. doi: 10.1093/ckj/sfs002. Epub 2012 Mar 15.
2
The renaissance of complement therapeutics.补体疗法的复兴。
Nat Rev Nephrol. 2018 Jan;14(1):26-47. doi: 10.1038/nrneph.2017.156. Epub 2017 Dec 4.
3
Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
免疫复合物介导的膜增生性肾小球肾炎和补体3肾小球病的诊断与管理挑战
Kidney Int Rep. 2024 Sep 21;10(1):17-28. doi: 10.1016/j.ekir.2024.09.017. eCollection 2025 Jan.
4
Functional Characterization of Anti-C3bBb Autoantibodies and C3 Glomerulopathy Phenotype.抗C3bBb自身抗体与C3肾小球病表型的功能特征
J Am Soc Nephrol. 2025 Feb 1;36(2):264-273. doi: 10.1681/ASN.0000000000000499. Epub 2024 Sep 26.
5
First Successful Treatment of a Patient with a Primary Immune Complex-Membranoproliferative Glomerulonephritis with Iptacopan: A Case Report.首例使用依他库帕成功治疗原发性免疫复合物膜增生性肾小球肾炎患者:病例报告
Case Rep Nephrol Dial. 2024 Aug 7;14(1):138-147. doi: 10.1159/000540013. eCollection 2024 Jan-Dec.
6
The ouroboros of autoimmunity.自身免疫的衔尾蛇。
Nat Immunol. 2024 May;25(5):743-754. doi: 10.1038/s41590-024-01815-y. Epub 2024 May 2.
7
Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series.非典型溶血性尿毒症综合征:一项哥伦比亚全国性儿科研究系列
Glob Pediatr Health. 2024 Feb 10;11:2333794X241231133. doi: 10.1177/2333794X241231133. eCollection 2024.
8
Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.依帕卡潘治疗特发性免疫复合物介导的膜增生性肾小球肾炎:APPARENT多中心随机3期研究方案
Kidney Int Rep. 2023 Oct 29;9(1):64-72. doi: 10.1016/j.ekir.2023.10.022. eCollection 2024 Jan.
9
C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis.C3肾小球病:致密物沉积病和C3肾小球肾炎。
Front Med (Lausanne). 2023 Nov 24;10:1289812. doi: 10.3389/fmed.2023.1289812. eCollection 2023.
10
Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases.培克妥昔单抗在C3肾小球病和其他补体介导的肾小球疾病患者2期研究中的临床安全性和有效性。
Kidney Int Rep. 2023 Aug 25;8(11):2284-2293. doi: 10.1016/j.ekir.2023.08.033. eCollection 2023 Nov.
聚类分析确定 C3 肾小球病/免疫复合物介导的膜增生性 GN 中的不同发病模式。
J Am Soc Nephrol. 2018 Jan;29(1):283-294. doi: 10.1681/ASN.2017030258. Epub 2017 Oct 13.
4
C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.C3肾小球病中的C4肾炎因子:病例系列
Am J Kidney Dis. 2017 Dec;70(6):834-843. doi: 10.1053/j.ajkd.2017.07.004. Epub 2017 Aug 24.
5
C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.C5 肾炎因子驱动 C3 肾小球疾病的生物学表型。
Kidney Int. 2017 Nov;92(5):1232-1241. doi: 10.1016/j.kint.2017.04.017. Epub 2017 Jul 14.
6
Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.C3肾小球病和Ig相关膜增生性肾小球肾炎中的抗B因子和抗C3b自身抗体
J Am Soc Nephrol. 2017 May;28(5):1603-1613. doi: 10.1681/ASN.2016030343. Epub 2017 Jan 17.
7
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.非典型溶血尿毒综合征与 C3 肾小球病:“改善全球肾脏病预后组织”(KDIGO)争议会议的结论。
Kidney Int. 2017 Mar;91(3):539-551. doi: 10.1016/j.kint.2016.10.005. Epub 2016 Dec 16.
8
Anti-complement-factor H-associated glomerulopathies.抗补体因子 H 相关肾小球病。
Nat Rev Nephrol. 2016 Sep;12(9):563-78. doi: 10.1038/nrneph.2016.99. Epub 2016 Jul 25.
9
Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.检测血清/血浆中补体转化酶活性以诊断C4NeF介导的C3肾小球肾炎
J Clin Immunol. 2016 Jul;36(5):517-27. doi: 10.1007/s10875-016-0290-5. Epub 2016 May 5.
10
Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.补体基因变异决定免疫球蛋白相关MPGN和C3肾小球病的风险,并预测长期肾脏结局。
Mol Immunol. 2016 Mar;71:131-142. doi: 10.1016/j.molimm.2016.01.010. Epub 2016 Feb 16.